165 related articles for article (PubMed ID: 7587850)
1. Release of platelet plasminogen activator inhibitor 1 in whole blood is increased in patients with type II diabetes.
Jokl R; Klein RL; Lopes-Virella MF; Colwell JA
Diabetes Care; 1995 Aug; 18(8):1150-5. PubMed ID: 7587850
[TBL] [Abstract][Full Text] [Related]
2. Platelet plasminogen activator inhibitor 1 in patients with type II diabetes.
Jokl R; Laimins M; Klein RL; Lyons TJ; Lopes-Virella MF; Colwell JA
Diabetes Care; 1994 Aug; 17(8):818-23. PubMed ID: 7956624
[TBL] [Abstract][Full Text] [Related]
3. Plasma t-PA and PAI-1 antigen concentrations in non-insulin dependent diabetic patients: implication for diabetic retinopathy.
Cho YW; Yang DH; Oh DY; Baick SH; Kim SK; Kim SJ; Hong SY
Diabetes Res Clin Pract; 1994 Jan; 22(2-3):123-8. PubMed ID: 8200293
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin-dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-diabetic Asians.
Nagi DK; Mohamed Ali V; Jain SK; Walji S; Yudkin JS
Diabet Med; 1996 Jan; 13(1):59-64. PubMed ID: 8741814
[TBL] [Abstract][Full Text] [Related]
5. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels.
Gürlek A; Bayraktar M; Kirazli S
Diabetes Care; 2000 Jan; 23(1):88-92. PubMed ID: 10857975
[TBL] [Abstract][Full Text] [Related]
6. Effects of gliclazide on platelet aggregation and the plasminogen activator inhibitor type 1 level in patients with type 2 diabetes mellitus.
Konya H; Hasegawa Y; Hamaguchi T; Satani K; Umehara A; Katsuno T; Ishikawa T; Miuchi M; Kohri K; Suehiro A; Kakishita E; Miyagawa J; Namba M
Metabolism; 2010 Sep; 59(9):1294-9. PubMed ID: 20070990
[TBL] [Abstract][Full Text] [Related]
7. Metalloproteinase-2 and -9 in diabetic and nondiabetic subjects during acute coronary syndromes.
Derosa G; Cicero AF; Scalise F; Avanzini MA; Tinelli C; Piccinni MN; Peros E; Geroldi D; Fogari E; D'Angelo A
Endothelium; 2007; 14(1):45-51. PubMed ID: 17364896
[TBL] [Abstract][Full Text] [Related]
8. The effect of obesity on fibrinolytic activity and plasma lipoprotein (a) levels in patients with type 2 diabetes mellitus in Korea.
Park YS; Park S; Park KS; Kim SY; Lee HK; Koh CS; Min HK; Kim JQ
Diabetes Res Clin Pract; 1994 May; 24(1):25-31. PubMed ID: 7924883
[TBL] [Abstract][Full Text] [Related]
9. Insulin therapy in type 2 diabetic subjects suppresses plasminogen activator inhibitor (PAI-1) activity and proinsulin-like molecules independently of glycaemic control.
Jain SK; Nagi DK; Slavin BM; Lumb PJ; Yudkin JS
Diabet Med; 1993; 10(1):27-32. PubMed ID: 8435984
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis and diabetic retinopathy in NIDDM.
Mansfield MW; Grant PJ
Diabetes Care; 1995 Dec; 18(12):1577-81. PubMed ID: 8722054
[TBL] [Abstract][Full Text] [Related]
11. Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications.
Kesavulu MM; Giri R; Kameswara Rao B; Apparao C
Diabetes Metab; 2000 Nov; 26(5):387-92. PubMed ID: 11119018
[TBL] [Abstract][Full Text] [Related]
12. Lipoprotein(a), tissue plasminogen activator and plasminogen activator inhibitor 1 levels in hyperlipidaemic patients in Kuwait.
Akanji AO; Abdullah A; Tahzeeb S
Eur J Clin Invest; 1997 May; 27(5):380-6. PubMed ID: 9179544
[TBL] [Abstract][Full Text] [Related]
13. Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM.
Anfossi G; Mularoni EM; Burzacca S; Ponziani MC; Massucco P; Mattiello L; Cavalot F; Trovati M
Diabetes Care; 1998 Jan; 21(1):121-6. PubMed ID: 9538982
[TBL] [Abstract][Full Text] [Related]
14. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.
Nagi DK; Yudkin JS
Diabetes Care; 1993 Apr; 16(4):621-9. PubMed ID: 8462390
[TBL] [Abstract][Full Text] [Related]
15. Fibronectin and lipoprotein(a) are inversely related to plasminogen activator inhibitor type-1 levels in Type 2 diabetic patients without complications.
Testa R; Bonfigli AR; Sirolla C; De Grazia G; Compagnucci P; Manfrini S; Fumelli D; Testa I
Diabetes Nutr Metab; 2000 Oct; 13(5):269-75. PubMed ID: 11105969
[TBL] [Abstract][Full Text] [Related]
16. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes.
Grant PJ
Diabetes Care; 1996 Jan; 19(1):64-6. PubMed ID: 8720537
[TBL] [Abstract][Full Text] [Related]
17. Does chronic smoking influence fibrinolytic potential in type 1 diabetes mellitus?
Simpson AJ; Booth NA; Moore NR; Gray RS
Diabet Med; 1998 Aug; 15(8):683-7. PubMed ID: 9702473
[TBL] [Abstract][Full Text] [Related]
18. Effects of insulin on cholesterol synthesis in type II diabetes patients.
Scoppola A; Testa G; Frontoni S; Maddaloni E; Gambardella S; Menzinger G; Lala A
Diabetes Care; 1995 Oct; 18(10):1362-9. PubMed ID: 8721938
[TBL] [Abstract][Full Text] [Related]
19. Diabetic patients without vascular complications display enhanced basal platelet activation and decreased antioxidant status.
Véricel E; Januel C; Carreras M; Moulin P; Lagarde M
Diabetes; 2004 Apr; 53(4):1046-51. PubMed ID: 15047620
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen activator inhibitor-1 in nonobese subjects with non-insulin-dependent diabetes mellitus.
Ito Y; Okeda T; Sato Y; Ito M; Sakata T
Proc Soc Exp Biol Med; 1996 Mar; 211(3):287-91. PubMed ID: 8633110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
